U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336875) titled 'Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML' on Jan. 04.
Brief Summary: The purpose of this clinical trial is to evaluate the safety and efficacy of CAR-ITNK cells therapy targeting CD70 and CLL1 in participants with relapsed/refractory Acute Myeloid Leukemia. Participants will receive a single infusion of CAR-ITNK cell therapy targeting CD70 and CLL1 and complete follow-ups over the next three years.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
R/R AML
Intervention:
BIOLOGICAL: CAR-ITNK Cells targeting CD70 and CLL1
Administer a single infusion of CAR-ITNK Cel...